Category: Business

Categories
Business

Marjorie Taylor Greene presents ‘a major problem for the GOP,’ Republican strategist says

Lawmakers, activists call for removal from Congress

Republican strategist Evan Siegfried told CNBC that Rep. Marjorie Taylor Greene, R-Ga. and “their hideous views pose a serious problem for the GOP” as the House of Representatives prepares to vote on Thursday on a resolution to remove Greene’s committee duties.

“You don’t just force that [Republican] To say party whether they agree with them or not, but they are a gift to Biden and the Democrats because they don’t allow Republicans to effectively communicate their message against President Biden’s agenda, “said Siegfried, the author of “GOP GPS: How to Find the Millennials and Urban Voters the Republican Party needs to survive. “

The move to remove Greene from the committee’s duties comes amid widespread criticism of a number of extreme remarks she made prior to winning her congressional seat, including pointing out that school shootings like the one at Sandy Hook took place in 2012 and a parkland survivor were mocked.

Minority chairman Kevin McCarthy, R-Calif., Released a statement Wednesday condemning Greene’s earlier comments but said the decision to remove them from committees was a distraction from Congress.

“The Democrats are resolving to raise the temperature by taking the unprecedented step to advance their partisan takeover of the other party’s committee assignments,” McCarthy said.

Siegfried told The News with Shepard Smith that McCarthy and the Republicans missed an opportunity because they did nothing.

“Leader McCarthy and the House GOP have given up their responsibilities by saying that they will now let the whole House decide their fate,” said Siegfried. “It shouldn’t be difficult to take action against someone with morally disgusting views.”

On Wednesday, the Democrats in the House Rules Committee gave the go-ahead for the vote, saying they had to act because Republicans didn’t take action.

House majority leader Steny Hoyer, D-Md., Tweeted after speaking with minority leader Kevin McCarthy, R-Calif. “”

Greene took advantage of the Democrats’ actions and began fundraising Tuesday based on allegations that she was wrongly aligned with her beliefs. She tweeted that she has since raised $ 160,000 for her efforts.

Democratic strategist Eric Koch told The News with Shepard Smith that Democrats shouldn’t worry that their opposition may benefit Greene’s grassroots.

“Marjorie Taylor Greene is a dangerous Q-anon conspiracy theorist and must be held accountable for her extremist, anti-Semitic views and the trauma she has brought on survivors of violence,” said Koch. “Democrats shouldn’t worry what their base might think of this.”

Speaking at the rules committee hearing, senior Oklahoma Republican Tom Cole said he was concerned that allowing Democrats to unilaterally take action against a legislature in another party would set a dangerous precedent.

Committee chairman Jim McGovern, D-Mass. Said it was okay to set a precedent for a member to advocate violence against his colleagues. “If that’s not why I don’t know what the hell is,” said McGovern.

Koch said, “If the Republicans would rather side with someone who thinks the parkland shooting is a joke or if Jewish space lasers set off forest fires, that’s their choice.”

The vote will force Republicans to put on record whether Greene should be reprimanded for her earlier comments.

Siegfried predicted that GOP officials “will be praised by the media and loathed by the grassroots, and as a result many will see them as part of the” establishment “and somehow personally against them.”

Siegfried added that Republican elected officials looked away from many of Trump’s “absurdities” believing the party would return to its pre-Trump era once he was out of office.

“They didn’t expect the grassroots not to want to go back there, and they also voted for pro-Trump officials who will continue to advocate what can only be described as insane and morally disgusting views.”

A parallel drama also played out in the house with Rep. Liz Cheney, R-Wy. Supporters of former President Donald Trump want to remove Cheney from her No. 3 leadership position for supporting Trump’s impeachment for inciting insurrection

Siegfried said the debate among Republicans in the House about keeping Cheney signals to him that the grassroots Trump had created has not changed.

“They will be present for years to come, promoting individuals and ideas that are more like Greene than Rep. Cheney,” Siegfried said.

A source told NBC News that Cheney refused to apologize for the charges against Trump during an allegedly noisy GOP meeting in camera.

Koch said the move against Cheney showed that “the Republican Party is Trump and Marjorie Taylor Greene’s party”.

Categories
Business

After a Rocky Begin, Novavax Vaccine May Be Right here by Summer season

After a Rocky Start, Novavax Vaccine Could Be Here by Summer

Dr. Thomas Campbell, who oversees the testing site at UCHealth in Colorado, said he had received more than 2,000 emails and hundreds of calls from potential volunteers. He said the excitement about Pfizer and Moderna vaccines has piqued interest in vaccination, but their scarcity is leading some people to investigate other options. The news about the Novavax trial in Great Britain has also sparked excitement: so far, 224 people have registered at his location.

“If they’re in a clinical trial with an experimental vaccine, they may get a vaccine sooner than usual,” he said.

If Novavax is successful, the new vaccine could add to an expanded portfolio of vaccinations in the US by late spring. Moderna and Pfizer have agreements with the United States to deliver 400 million doses by the middle of the year, enough to fully vaccinate 200 million people, and both companies are in talks to deliver an additional 100 million doses each after that.

Johnson & Johnson, who recently reported that its single-dose vaccine was effective in a large US study, could get approval this month but may not be able to ship any significant quantities to the US until April. AstraZeneca’s U.S. study is also ongoing, and the company has signed a deal to provide Americans with 300 million doses of its two-shot vaccine.

But any number of obstacles could affect Novavax’s progress. As other vaccines became more widespread, participants in the Novavax study could drop out. Although the results in the UK were promising, the US study could produce different results. Or the company might fail to demonstrate to regulators that it can reliably manufacture its vaccine on a large scale. With the US likely to have three approved vaccines available to the public soon, the company is under pressure to move forward or at risk of losing ground to competitors.

Novavax, based in Gaithersburg, Md., Struggled for years to get a successful product to market, and in 2019 its stock traded so low it was in danger of being delisted from the Nasdaq. Then, last spring and summer, two big deals saved it from doom. In May, the Coalition for Epidemic Preparation Innovations awarded the company up to $ 388 million to make its Covid vaccine available worldwide. In July, it was selected by the federal government’s Operation Warp Speed ​​program to develop and sell its vaccine to the United States. Later in the summer, the company reported encouraging results in preliminary studies.

However, the company struggled last fall to begin the U.S. process with its previous October target. Novavax has put great emphasis on manufacturing and has plants around the world. However, making these vaccines is a delicate and unpredictable process even for seasoned drug makers, and Novavax has struggled to outgrow the smaller batches required for early studies.

Categories
Business

Vaxart shares plunge on weak antibody response to oral vaccine

Vaxart shares plunge on weak antibody response to oral vaccine

An experimental coronavirus oral vaccine showed promising results in an early clinical trial of 35 healthy adults, Vaxart of South San Francisco said on Wednesday. Despite the results, Vaxart’s stock fell about 57%.

Vaxart scientists divided volunteers between the ages of 18 and 54 into three groups. The first group received two low doses of the vaccine – called VXA-CoV2-1 – 29 days apart, while the remaining groups received a single low or high dose.

The vaccine, contained in a small tablet, produced a type of T cell responsible for killing virus-infected cells in about 75% of the volunteers who received a single low or high dose. The reported reactions are higher than with the vaccines from Moderna and Pfizer.

However, neutralizing antibodies were not detected in volunteers after a single dose, Vaxart said. Researchers believe that the antibodies play an important role in the defense of cells against the virus. The company said it is currently testing second-dose antibody responses after antibodies were detected in two-dose volunteers’ nasal swab samples.

Isaac Bogoch, an infectious disease specialist and professor at the University of Toronto, said the company’s shares could fall after the first dose due to the lack of neutralizing antibodies.

“The immune response is diverse,” he said, adding that one aspect of the immune response is to make antibodies, especially neutralizing antibodies. “While it is great to see that there seems to be a decent T-cell response, the lack of antibodies detected is problematic and can reduce the effectiveness of this vaccine.”

The company said no serious adverse events were reported in the Phase 1 study, with side effects generally being mild. Volunteers reported common side effects such as headache and fatigue, and there was a “slight increase” in the high-dose group of loose stool cases, the company said.

The data will be presented on Wednesday afternoon at the New York Academy of Sciences symposium.

“The most exciting thing about the [phase one data] is that we can get a very, very strong T-cell response even after one dose, “Sean Tucker, Vaxart’s chief scientific officer, told CNBC in a telephone interview, adding that T-cells do compared to antibodies fighting the virus is likely to be “underestimated”.

The biotech company said the vaccine has the potential to provide better protection against current and emerging strains of the virus than existing vaccines. Moderna, Johnson & Johnson and Novavax have announced in the past few days that their vaccines may be less effective against B.1.351, a highly contagious strain found in South Africa. US officials have raised concerns that Covid may continue to mutate and defy the protection of existing vaccines.

Vaxart’s vaccine contains DNA instructions for making the spike protein that allows the virus to enter human cells, as well as instructions for making the N protein, which is involved in other processes. Tucker said the inclusion of the N protein could cause the vaccine to retain its ability to work against emergent strains.

Many other vaccines under development chose spike protein as a “primary target,” he said. “But the problem with that [spike] Protein it definitely mutates more over time. We also added the N protein, which is highly conserved in the virus. “

According to Vaxart, the vaccine is the only oral tablet in the US that has been tested in humans. Similar technology is being used to develop vaccines against influenza and norovirus.

The company was investigated and investigated by the federal government late last year for allegedly exaggerating its involvement in Operation Warp Speed, former President Donald Trump’s vaccines and treatments program. A June press release said that “Vaxart’s Covid-19 vaccine has been selected for US government Operation Warp Speed,” which rocketed its stocks.

However, it found the company had received no federal government funding for vaccine doses and was only participating in preliminary U.S. studies to identify potential areas for possible Warp Speed ​​partnership and support, according to the New York Times.

Tucker told CNBC the company is in talks with the US and other governments to find possible ways to collaborate on its vaccine.

If Vaxart’s vaccine goes through other clinical trials and US approval, it could offer advantages over needle-based vaccines.

Dr. Paul Offit, a member of the FDA’s Advisory Committee on Vaccines and Allied Biological Products, said that an orally taken vaccine may be better accepted by the public who may be afraid of needles. Two US-approved Covid-19 vaccines – from Pfizer and Moderna – are injected into the arm and require two injections three to four weeks apart.

Vaxart said his vaccine is stable even at room temperature and does not require a freezer, which means it “can be stored and delivered to mass populations around the world”. In comparison, Pfizer’s vaccine must be stored in ultra-cold freezers that keep it between minus 112 and minus 76 degrees Fahrenheit. Moderna vaccine must be delivered between 13 and 5 degrees Fahrenheit.

Vaxart said the vaccine also doesn’t require any special medical training and can be taken at home. This will help comply with social distancing guidelines while relieving the burden on the health system.

The company said it was still critical whether it was single- or two-dose therapy.

A phase 2 study is expected “in the next few months,” Tucker said. In its “Fastest Accelerated Timeline,” the company expects Phase two and three studies to be completed by early 2022.

–CNBC’s Hugh Son contributed to this report.

Categories
Business

Uber Eats, Chipotle Rise as Tremendous Bowl Business Newcomers

Uber Eats, Chipotle Rise as Super Bowl Commercial Newcomers

The 30 percent capacity game from Raymond James Stadium in Tampa, Florida features Patrick Mahomes of the Kansas City Chiefs, the defending champions, against Tom Brady, who is playing in his 10th Super Bowl this time, a new Tampa Bay star Buccaneers. Although Tampa and Kansas City are midsize television markets and NFL ratings have dropped this season, some TV executives believe the quarterback matchup could draw 100 million or more viewers. Last year’s game had a television audience of 99.9 million.

Fox, which aired the 2020 competition, sold all of its Super Bowl ad space before Thanksgiving 2019 and generated $ 448.7 million in ad revenue – a record, according to research firm Kantar. Sales have been slower this year and CBS only filled its 70 or so slots last week.

The attention generated by Super Bowl advertisements extends beyond the game. Twice as many people could see the commercials on social media sites as they did during the broadcast, said Jonah Berger, a marketing professor at the University of Pennsylvania’s Wharton School. Brands also hope their ads are distinctive or dramatic enough to cause a stir after the final whistle.

“But this echo effect, which many brands are banking on, will not be so great this year,” said Berger. “Fewer people will speak in the office on Monday morning because they won’t be in the office.”

These days, commercials are only part of the Super Bowl marketing for many companies. Verizon’s plan is to sponsor game sessions on Twitch, a Verizon-branded virtual stadium in the online video game Fortnite, and a livestream post-game concert featuring Alicia Keys and Miley Cyrus. The company’s traditional TV commercial “was the easiest thing we do,” said Diego Scotti, Verizon’s chief marketing officer.

Matt Manning, the executive director of the MKTG agency, said the Super Bowl was “probably the premier meeting event” for the advertising industry in a typical year, adding that his colleagues often had trouble getting a hotel room within 20 miles book stadium. He said he’s not going this year because of the pandemic.

It is also the first time in 15 years that Jeremy Carey, CEO of Optimum Sports, has not participated in the game. He said his company, the sports marketing division of advertising firm Omnicom Media Group, handles up to 20 percent of Super Bowl advertisers. Even at some distance from the field, he expects to feel tense on Sunday.

“It’s different from anything,” said Mr. Carey. “When you look at the top performing programs, nothing comes close. There are nervous nervousnesses that go with it – but if you didn’t have that as a Super Bowl marketer, I’d question your humanity. “

John Koblin contributed to the coverage.

Categories
Business

CDC director says faculties can safely reopen with out vaccinating lecturers

Biden's incoming CDC director says Trump administration 'muzzled' scientists

Rochelle Walensky, who was nominated as director of the Centers for Disease Control and Prevention, speaks after U.S. President-elect Joe Biden started his team dealing with the Covid-19 on December 8 at The Queen in Wilmington, Delaware. Pandemic commissioned, 2020.

Jim Watson | AFP | Getty Images

Teachers don’t have to get Covid-19 vaccinations before schools can safely reopen, the head of the Centers for Disease Control and Prevention said Wednesday.

“There is mounting data to suggest schools can be reopened safely and that reopening safely does not mean teachers need to be vaccinated,” CDC Director Rochelle Walensky told reporters during a White House press conference on Covid-19.

“Teacher vaccinations are not a requirement for schools to reopen safely,” she added.

The CDC Advisory Committee on Immunization Practices voted for “key frontline workers”, including teachers, to have their turn to receive a Covid-19 vaccine after prioritizing healthcare workers and residents of long-term care facilities were. However, it can take a while for most teachers to get their recordings as US officials work to speed up the pace of vaccinations.

Even so, school systems in the US have been under pressure to reopen after switching to distance learning last year due to the coronavirus pandemic that infected more than 26.4 million Americans and killed at least 447,077 people in just over a year had.

Some parents had to stay home to watch their children instead of going to work. Meanwhile, teachers and other faculties have raised concerns about return to school that could potentially endanger their health.

A study by the CDC released late last month found little evidence of the virus spreading to schools in the US and abroad when precautions were taken, such as wearing masks, social distancing, and ventilation rooms.

The Biden government has released a bailout plan for Covid that includes $ 170 billion to reopen schools and universities. Some of the money would be used to scale tests. The government has stated that testing is a “critical” strategy for controlling the spread of the virus, but added testing is still not widely used and the US is still not effectively using the tests it has.

Walensky previously said schools should be the first to open and the last to close in the pandemic.

Jeff Zients, President Joe Biden’s Covid-19 tsar, said Wednesday that Biden was “very clear” that he would like schools to “reopen and stay open”.

“That means every school has the equipment and resources to open safely,” he said during the press conference, calling on Congress to “do its part” by approving Biden’s Covid rescue plan. “Not just private schools or schools in affluent areas, but all schools.”

Categories
Business

‘I Could Destroy You’ Is Shut Out by Golden Globes

‘I May Destroy You’ Is Shut Out by Golden Globes

Unpredictability is the TV portion of the Golden Globes’ biggest weakness, and it’s also its biggest strength. Ordinarily, you can count on the handful of voters at the Globes to make some startling decisions and celebrate some deserving but obscure candidates the Emmys overlook.

Call it inspired moodiness or the broken clock theory; Either way, it’s part of the charm of the awards. Let the Globes film hold the weight to set the odds for Oscar season. All low-stakes television awards are surprises. Here are some of them – for better or worse – for 2021 and some standout TV products from last year that were left out.

“I can destroy you”

Well that was a crime. Michaela Coel’s deservedly acclaimed limited series on rape and its aftermath was one of the most impressive storytelling feats not only of the year, but perhaps of the last decade. Apparently not to the globes; it was as absent from the Hollywood Foreign Press Association’s list as it was from its critics’ best-of-2020 lists.

“Emily in Paris”

No, that’s not a typo. Darren Star’s fantasy for Netflix about a young American entering the French luxury marketing business received some harsh reviews on both sides of the Atlantic. Explanation, s’il vous plaît? The Golden Globes are fond of honoring new shows and young talent (star Lily Collins also received an actor nomination). Also, the prizes are given by the HFPA, and now … I think “Paris” is in the title?

“Ratched”

The consequence of the HFPA’s love for the new is its weakness for stars, stars, stars. This misunderstood origin story for “One Flew Over the Cuckoo’s Nest” had many of them, at least in casting and production. (It’s the product of Ryan Murphy’s new association with Netflix.)

‘Unorthodox’

In an intimidatingly strong limited series year, this four-part Netflix series about a young Hasidic woman (Shira Haas) fleeing from her oppressive Brooklyn life felt like quiet, excellent work that could be overlooked during the awards season. But the globes remembered that drama – well worth checking out if you missed it in March – as well as the notable Haas.

‘Mrs. America’

This has been a big year for limited series – do you notice a topic? – Perhaps it is not shocking that there was no place for this story of the struggle for the Equal Rights Amendment, informed but not encumbered by a sense of feminist history. But you couldn’t have booted the ridiculous “The Undoing” for it?

Brendan Gleeson, “The Comey Rule”

The Globes failed to nominate this chunky miniseries that dramatized the role of former FBI Director James Comey in the election and administration of Donald Trump, and did a good job doing it. But there is something to be said for good performance on a bad show, and as a former president, Gleeson brought a different quality to the many nightly comedy impressions, a sense of impending gangster threat.

Rhea Seehorn, “Better call Saul”

The look at Seehorn’s subtly devastating performance in the prequel “Breaking Bad” has become a kind of perverse show tradition. But her work last season, when her Kim Wexler got caught up in the crime spiral of Jimmy McGill (Bob Odenkirk), was particularly deserved.

“Bridgerton”

His excitement, sex appeal, and star producer power may have made this Shonda Rhimes romance a typical Globes choice, but recognition in the drama category proved as elusive as Lady Whistledown. (And honestly, as much as I enjoyed season one, I would have added “P-Valley” or “Better Call Saul” beforehand.)

‘Little Ax’

This “surprise” is not a comment on the quality of Steve McQueen’s ambitious collection of five filmed stories – but it may surprise some readers that these films were nominated in this category. At least as far as the globes are concerned, they are television! (Cue “The More You Know” logo.)

Categories
Business

UK targets unfold of South Africa variant

UK targets spread of South Africa variant

An ambulance worker collects Covid-19 test kits during a door-to-door bulk testing operation in Maidstone, United Kingdom on Tuesday, February 2, 2021.

Bloomberg | Bloomberg | Getty Images

LONDON – UK is working hard to contain the spread of additional mutations in the coronavirus. The more worrying variant, first spotted in South Africa, occurs spontaneously in different parts of the country.

UK Health Secretary Matt Hancock said the country was “coming down hard” on the South African variant after 105 cases were reported, and 11 of those cases had no connection to international travel.

Because of this, the UK has launched an expanded testing program to include around 80,000 people living in areas where cases with the mutation have been found. Tests are offered door-to-door and positive cases are then scored to see if they are caused by the South African variant.

People in these areas have been told to consider limiting the time they spend outside their homes as health officials struggle to prevent the spread of another contagious variant. A mutation now known as the “British Mutation” has already become the dominant tribe in many parts of the country.

Earlier this week, Public Health England released another technical briefing warning that a handful of coronavirus cases of the variant first found in the UK were in fact further mutated to include the E484K mutation, first seen in the variant of was South Africa.

Mutations in a virus are normal; Viruses are constantly mutating. However, experts and policy makers are concerned about mutations that allow the virus to spread much faster.

The South African variant had other concerned experts who were concerned that coronavirus vaccines developed last year may not be as effective against it. There were also concerns that the South African variant might evade antibodies.

Vaccine manufacturers have indicated that there is little evidence that their shots are ineffective against new variants, and that they should be able to adapt their vaccines to new variants in a few weeks if necessary.

On Wednesday, the British pharmaceutical company GlaxoSmithKline and the German biotech company CureVac announced a € 150 million contract to develop Covid vaccines that target multiple variants in one product. The partners hope to be able to bring such vaccines to market in 2022.

The UK’s vaccination program continues to pick up pace and is well on its way to growing its four top priority groups (those over 70, residents and workers in nursing homes, frontline health and social workers and the most clinically vulnerable) to around 15 million vaccinate people until mid-February.

By February 1, over 9.6 million people had received a first dose of the vaccine, and just under 500,000 had received two doses, according to government figures.

Categories
Business

The AstraZeneca vaccine is proven to drastically reduce transmission of the virus.

The AstraZeneca vaccine is shown to drastically cut transmission of the virus.

Developed by Oxford University and AstraZeneca, the vaccine not only protects people from serious illness and death, but also significantly slows down the transmission of the virus, according to a new study – a finding that underscores the importance of mass vaccination as a way out of the pandemic.

The study by researchers at Oxford University is the first to document evidence that any coronavirus vaccine can reduce transmission of the virus.

Researchers measured the effects on transmission by wiping participants down each week to look for signs of the virus. In the absence of a virus, it cannot be spread even if someone is infected. And they found a 67 percent reduction in positive swabs among those vaccinated.

The results, detailed by Oxford and AstraZeneca researchers in a non-peer-reviewed manuscript, found that the vaccine could reduce transmission by nearly two-thirds.

Matt Hancock, the UK Health Secretary, hailed the results on Wednesday as “absolutely outstanding”.

“We now know that the Oxford vaccine will also reduce transmission and help us all get out of this pandemic,” Hancock said in an interview with the BBC on Wednesday morning.

The results, he said, “should give everyone confidence that this shock will not only serve to protect you, but also to keep you from passing the virus on to others.”

Some scientists studying the limited information published warned that further analysis of the data would be needed before such broad conclusions could be drawn.

“While this would be extremely welcome news, we need more data before this can be confirmed, so it is important that we all continue to follow social distancing guidelines after vaccination,” said Dr. Doug Brown, executive director of the British Immunology Society.

The Oxford and AstraZeneca researchers also found that a single dose of the vaccine was 76 percent effective against Covid-19. The data was measured three months after the first shot, with no initial three week period required for the protection to take effect.

The encouraging results support the UK and other countries strategy of prioritizing the provision of as many first doses of vaccine as possible and ignore concerns that people will receive their second doses later than originally planned.

The latest data does not affect the debate over whether to further reduce doses of the two US-approved vaccines Pfizer-BioNTech and Moderna, as the data on AstraZeneca’s candidates cannot be transferred to other vaccines.

Some scientists have urged the United States to follow the example of the UK and other countries who have chosen to postpone the second dose of vaccine for up to 12 weeks. But U.S. federal officials refused, saying such a move would not be supported by clinical trial data for the two vaccines currently available nationwide. Tuesday’s results could add to pressure on US health officials to postpone AstraZeneca’s second dose of vaccine, even though it has not yet been approved by the country.

The vaccine appeared to be more effective when the interval between the two shots was longer than the four-week interval originally intended, the Oxford and AstraZeneca researchers found. Among clinical trial participants who received two standard strength doses at least three months apart, the vaccine was 82 percent effective, compared with 55 percent when the doses were given less than six weeks apart.

Covid19 vaccinations>

Answers to your vaccine questions

Am I eligible for the Covid vaccine in my state?

Currently more than 150 million people – almost half of the population – can be vaccinated. But each state makes the final decision on who goes first. The country’s 21 million healthcare workers and three million long-term care residents were the first to qualify. In mid-January, federal officials asked all states to open eligibility to anyone over 65 and adults of any age with medical conditions that are at high risk of becoming seriously ill or dying of Covid-19. Adults in the general population are at the end of the line. If federal and state health authorities can remove bottlenecks in the distribution of vaccines, everyone over the age of 16 is eligible as early as spring or early summer. The vaccine has not been approved in children, although studies are ongoing. It can take months before a vaccine is available to anyone under the age of 16. For the latest information on vaccination guidelines in your area, see your state health website

Is the Vaccine Free?

You shouldn’t have to pay anything out of pocket to get the vaccine, despite being asked for insurance information. If you don’t have insurance, you should still get the vaccine for free. Congress passed law this spring banning insurers from applying cost-sharing such as a co-payment or deductible. It consisted of additional safeguards prohibiting pharmacies, doctors, and hospitals from charging patients, including uninsured patients. Even so, health experts fear that patients will end up in loopholes that make them prone to surprise bills. This may be the case for people who are charged a doctor’s visit fee with their vaccine, or for Americans who have certain types of health insurance that are not covered by the new regulations. When you get your vaccine from a doctor’s office or emergency clinic, talk to them about possible hidden costs. To make sure you don’t get a surprise invoice, it is best to get your vaccine at a Department of Health vaccination center or local pharmacy as soon as the shots become more widely available.

Can I choose which vaccine to get?How long does the vaccine last? Do I need another next year?

That is to be determined. It is possible that Covid-19 vaccinations will become an annual event just like the flu vaccination. Or the vaccine may last longer than a year. We’ll have to wait and see how durable the protection from the vaccines is. To determine this, researchers will track down vaccinated people to look for “breakthrough cases” – those people who get Covid-19 despite being vaccinated. This is a sign of a weakening of protection and gives researchers an indication of how long the vaccine will last. They will also monitor the levels of antibodies and T cells in the blood of people who have been vaccinated to see if and when a booster shot might be needed. It is conceivable that people might need boosters every few months, once a year, or just every few years. It’s just a matter of waiting for the data.

Does my employer need vaccinations?Where can I find out more?

A vaccination strategy that cuts doses by three months “might be the optimum for pandemic vaccine rollout when supplies are limited in the short term,” the researchers wrote.

The newly published study builds on data published late last year. The vaccine was found to be 62 percent effective at two standard strength doses. In these initial findings, the vaccine effectiveness was 90 percent much higher when the first dose of the vaccine was given at half strength.

The researchers from Oxford and AstraZeneca initially attributed the different levels of effectiveness to the lower strength of the initial dose. Gradually, however, they came to a different conclusion: the time between doses was the more likely explanation.

In the United States, the Food and Drug Administration is waiting for data from a clinical trial that involved around 30,000 participants, mostly Americans. The results of this study are expected later this month.

The study is expected to provide AstraZeneca with enough safety data to enable it to obtain approval to make the emergency vaccine available by early March.

The United States has agreed to purchase 300 million doses of the vaccine from AstraZeneca, but neither the company nor the federal government has indicated when and in what quantities those doses will be available after the vaccine is approved.

Categories
Business

Delaying second AstraZeneca vaccine dose does work, examine exhibits

Delaying second AstraZeneca vaccine dose does work, study shows

A health worker shows a vial of the Covid-19 coronavirus vaccine from AstraZeneca-Oxford at Patan Hospital near Kathmandu on January 27, 2021.

PRAKASH MATHEMA | AFP | Getty Images

The UK’s decision to postpone AstraZeneca University Oxford’s second shot of coronavirus vaccine has proven to be an effective strategy, according to results from a new study.

Oxford University researchers found that the Covid-19 vaccine was 76% effective at preventing symptomatic infection for three months after a single dose, and that the rate of effectiveness increased with a longer interval before the first and second dose.

“The effectiveness of the vaccine after a single standard dose of the vaccine from the 22nd to the 90th day post-vaccination was 76% … and the modeled analysis showed that protection did not diminish during this initial 3-month period,” said the Study that was reviewed by The Lancet Medical Journal and published as a preprint on Tuesday found.

The effectiveness rate increased to 82.4% when at least 12 weeks were before the second dose. When the second dose was given less than six weeks after the first, the rate of effectiveness was 54.9%.

“These analyzes show that greater vaccine effectiveness is achieved with a longer interval between the first and second dose and that a single dose of vaccine is highly effective in the first 90 days, which further supports current policy,” the report said .

The UK’s current strategy is to vaccinate as many people as possible with a single dose first and postpone the second dose for up to 12 weeks. The idea is that a first dose will provide at least some of the protection and allow more people to have access to the vaccines while their availability is limited.

The decision to delay the administration of a second booster dose has sparked controversy, with some questioning whether it might reduce the effectiveness of the vaccine in preventing severe Covid-19 infection.

However, the UK Joint Committee on Vaccination and Immunization supported the approach. The UK is also delaying the second dose of Pfizer BioNTech vaccine, a move vaccine makers have warned about, arguing that there is no data to support a delay.

The study also provided key data on whether the vaccine reduced transmission of the virus, a previously unknown and crucial question for policy makers looking to lift measures to lock down the economy.

Based on weekly swabs from volunteers in the UK study, a 67% reduction in transmission was found after the first dose of the vaccine.

Effective strategy

This latest study supports the UK Government’s decision and concludes that vaccination programs “aiming to vaccinate a large proportion of the population with a single dose, with a second dose given after a period of three months, are an effective strategy to reduce disease and may be the optimum for pandemic vaccine introduction when supply is limited in the short term. “

The study used additional data from ongoing clinical trials of the vaccine. A separate announcement from AstraZeneca on Wednesday showed that the vaccine also prevented serious illness from Covid-19, with no serious cases and no hospital stays more than 22 days after the first dose.

The vaccine was approved by the UK Medicines Agency on December 30th and, as a shot made in the UK, makes up most of the country’s previously hailed successful vaccination program.

The UK is well on its way to vaccinating its four top priority groups (those over 70, residents and workers in nursing homes, frontline health and social workers and the most clinically vulnerable), which number around 15 million people by mid-February to have.

By February 1, over 9.6 million people had received a first dose of the vaccine, and just under 500,000 had received two doses, according to government figures.

Professor Andrew Pollard, chief investigator of the vaccine study at Oxford and co-author of the study, said, “These new data provide an important review of the intermediate data used by more than 25 regulatory agencies, including MHRA and EMA, to grant vaccine emergency approval.”

“It also supports the policy recommendation of the Joint Vaccination and Immunization Committee for a 12-week prime-boost interval as it seeks the optimal approach to initiation and assures us that people will be protected before 22 days after a single are dose of the vaccine. “

The researchers also hope to release data on the new coronavirus variants in the coming days and expect the results to be broadly similar to those already reported by other vaccine developers: that the current vaccines are effective against mutations in the virus.

Germany, France and Sweden currently do not recommend the AstraZeneca vaccine for people over 65 because of insufficient study data on this age group. However, the vaccine maker and the UK government have defended the sting, saying the data available shows it is safe and effective. Further analysis will be available shortly.

Categories
Business

Golden Globes 2021 Nominations: Predictions, The right way to Watch

Golden Globes 2021 Nominations: Predictions, How to Watch

The Golden Globes have always been a strange ritual. The statues are awarded by a secret group of foreign journalists, of whom only 89 vote. The grand prizes are divided into dramatic and comedic categories, often in a confusing way. Oddly enough, foreign language films are not allowed to compete for the most prestigious awards.

That year, however, the surreal nature of the affair was heightened by a question from the pandemic era: Are the globes actually happening?

The five nominees for best drama could easily have zero ticket sales. Almost every controversial film has been released online or is still waiting to be released. Many cinemas have now been closed for 11 months.

Small golden trophies are difficult to care for for many people, including some in Hollywood, when the coronavirus is still killing more than 1,000 Americans a day. Others will no doubt hail the Golden Globes as a goofy distraction – a dependable balm of celebrity deductibles and the malicious glee you’ve seen.

Amy Poehler and Tina Fey will return as hostesses. The ceremony is scheduled for February 28th and will air on NBC.

The globes supposedly exist to honor outstanding achievements in film and television. But the real reason this show has to go on is money. NBC pays the Hollywood Foreign Press Association and its production partner Dick Clark Productions an estimated $ 65 million per year for broadcast rights. About 18 million people turned up last year.

Globe nominations are sought-after marketing tools. Studios and streaming services will quickly launch expensive advertising campaigns based on the numbers. For the first time since the beginning of the pandemic, moviedom will have a national platform that can be used as a lift-up rally: “I’m still here!”

The globes can also help steer a driving Oscar race on some kind of course. (The Oscars are slated for April 25th.) David Fincher’s fading “flaw” about Old Hollywood could use a Globe nomination or five right now. While “Hillbilly Elegy” was widely ridiculed, Globes voters may have been able to take Glenn Close away by recognizing their scene-eating mamaw. (It would be her 15th nomination.)

In truth the globes do not predict much. Over the past 20 years, the Globes and the Oscars have agreed on the best picture winners 50 percent of the time. Last year, Globe voters voted “Once Upon a Time … In Hollywood” and the war drama “1917” as best in class. Neither won the Academy Awards, which recognized the genre busting “Parasite”.

In accordance with their rules, the group did not nominate Parasite, a foreign language film, for Best Picture Globe.

What crazy specials await you this time around when the nominations are announced starting at 8:35 a.m. Eastern on Wednesday:

Netflix, only a competitor on the film side of the Globes since 2016, will dominate to a staggering extent. There are domestic films in the competition – “Ma Rainey’s Black Bottom,” “Mank,” “Da 5 Bloods,” “The Prom” – as well as films it bought in pandemic-stricken traditional studios, particularly Aaron Sorkin’s “The Trial of “the Chicago 7.” Among the television categories, the streaming service has established crowd-pleasers (“The Crown”, “Ozark”) and brilliant new hits (“Bridgerton”, “The Queen’s Gambit”).

Amazon is also going to get a ton of nominations, with Regina King’s “One Night in Miami,” a fact-based drama about a meeting of four black luminaries that is positioned to nod for best drama, best director, and best screenplay Picking Best Supporting Actor (for Leslie), Odom Jr., who plays Sam Cooke). And Globe voters will surely honor “Borat Subsequent Movie”, which appeared on Amazon Prime Video in October, among others in the categories “Best Comedy” and “Music”.

Some forecasters are also betting that the disrespectful superhero series “The Boys” will receive a nomination for Best Television Drama from Amazon, which would be a big deal given that the popular show, now in season two, has been largely overlooked by award groups.

The Hollywood Foreign Press Association has been attacked in recent years for neglecting inclusion and diversity. At the latest ceremony, for example, the group once again presented an all-male list of directors who did not nominate women like Greta Gerwig (“Little Women”) and Olivia Wilde (“Bookmaker”).

Expect a correction this year. It looks like both King and Chloé Zhao (“Nomadland”) will be recognized. To this mix Spike Lee is likely to be added for “Da 5 Bloods”. The war drama sparked a strong critical reaction, and Lee has been nominated three times by the group (most recently for directing “BlacKkKlansman”).

And this year, his children Satchel and Jackson will serve as Golden Globe Ambassadors, a job that traditionally takes winners off the stage. It wouldn’t be a family matter if Spike wasn’t there too.

The best actor in a drama category can also reflect a wide range of talents, including Chadwick Boseman (“Ma Rainey’s Black Butt”), Steven Yeun (“Minari”), Delroy Lindo (“Da 5 Bloods”) and Riz Ahmed ( “Sound of Metal”) and Anthony Hopkins (“The Father”) all in the mix for nominations. Tom Hanks could rise up for his cross-border commuter “News of the World”.

But the actresses’ nominations are likely to make the noise.

Globus voters might include a legend, Sophia Loren, for her role as a Holocaust survivor who runs a daycare for children of local prostitutes on Netflix’s The Life Ahead. Or they could give this slot to an actress who represents the future, Zendaya, who received praise for her performance in Malcolm & Marie, a romantic black and white drama (Netflix again).

Meryl Streep, a 25-time Globe nominee and eight-time winner, has received two nominations for best actress in a comedy or musical, one for her exaggerated “prom” performance and one for playing a writer trying to stand out reconnect with her friends in “Let Them All Talk.” Streep would likely compete against Bulgarian actress Maria Bakalova for her ultra-raw but surprisingly sweet twist in “Borat Subsequent Moviefilm”.

The TV Supporting Actress category, as usual, has a variety of candidates that add a little suspense. Will voters give way to both Gillian Anderson and Helena Bonham Carter of The Crown? Also competing are Uzo Aduba (“Mrs. America”), Letitia Wright (“Small Ax”), Annie Murphy (“Schitt’s Creek”), Jessie Buckley (“Fargo”), Marielle Heller (“The Queen’s Gambit”) and Julia Garner (“Ozark”). Garner and Aduba won Emmys for their accomplishments last year.

Without a foreign-language film kerfuffle, the globes would not be. This time the group has an egg in the face because Lee Isaac Chung’s “Minari” has to make a foreign language contribution – although Mr. Chung is an American director, the film was shot in the US and funded by American companies and it focuses on an immigrant family, who pursues the American dream.

But the characters in “Minari” mostly speak Korean. As a result, the Globe rules require that they be relegated to the best foreign language film race. It cannot be considered for the grand prize.

“Hamilton”, on the other hand, will likely benefit from the group’s rules. As a recorded stage performance, “Hamilton” does not qualify for the Oscars. But the HFPA has no such hang-up. So expect Lin-Manuel Miranda’s musical to show up for Best Comedy or Musical Nominee.